1. Articles from ncbi.nlm.nih.gov

  2. 1513-1536 of 1681 « 1 2 ... 61 62 63 64 65 66 67 ... 68 69 70 »
    1. TNF receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome (IPS). A joint Pediatric Blood and Marrow Transplant Consortium (PBMTC) and Children's Oncology Group (COG) study (ASCT0521).

      "Thirty-nine patients (median age 11y, range 1-17y) were enrolled, with 11 of 39 patients non-evaluable due to identification of pathogens from their pre-therapy BAL. In the remaining 28 patients, the median FiO2 at study entry was 45%, with 17 of 28 requiring mechanical ventilation. Complete responses were seen in 20 (71%) patients, with a median time to response 10 days (range 1-24). Response rates were higher for patients not requiring mechanical ventilation at study entry (100% vs. 53%,p=0.01). Overall survival at 28 days and 1-year post-therapy were 89% (95% CI:70-96) and 63% (95% CI:42-79) respectively ...

      Read Full Article
      Mentions: Treatment COG
    2. Driving CAR-based T-cell therapy to success.

      "T cells that have been genetically modified, activated, and propagated ex vivo can be infused to control tumor progression in patients who are refractory to conventional treatments. Early-phase clinical trials demonstrate that the tumor-associated antigen (TAA) CD19 can be therapeutically engaged through the enforced expression of a chimeric antigen receptor (CAR) on clinical-grade T cells. Advances in vector design, the architecture of the CAR molecule especially as associated with T-cell co-stimulatory pathways, and understanding of the tumor microenvironment, play significant roles in the successful treatment of medically fragile patients."

      Read Full Article
      Mentions: Refractory
    3. NK cells in the tumor microenvironment.

      "Preclinical studies have shown that, while NK cells efficiently kill circulating tumor cells of almost any origin, they seem to have very little effect against the same type of tumor cells when these have extravasated. The ability to kill extravasated tumor cells is, however, is dependent of the level of activation of the NK cells, as more recent published and unpublished studies, discussed below, have demonstrated that interleukin-2-activated NK cells are able to attack well-established solid tumors."

      Read Full Article
      Mentions: NK Cells
    4. MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis.

      "Thus, two MIBG-avid metastatic patterns emerged: "limited-focal" and "extensive-diffuse". The median numbers of affected body segments in MYCN-amplified (MNA) tumours were 5 (European cohort) and 4 (COG cohort) compared to 9 and 11, respectively, in single-copy MYCN (MYCNsc) tumours (P < 0.001). Patients with exclusively focal metastases were more likely to have a MNA tumour (60 % and 70 %, respectively) than patients with the other types of metastases (23 % and 28 %, respectively; P < 0.001). In a multivariate Cox regression analysis, focal metastases were associated with a better event-free and overall survival than the other types of metastases in patients with ...

      Read Full Article
      Mentions: COG Imaging MYCN
    5. Dexmedetomidine and hydromorphone: A novel pain management strategy for the oncology ward setting during anti-GD2 immunotherapy for high-risk neuroblastoma in children.

      "Treatment of neuroblastoma with targeted immunotherapy using chimeric anti-GD2 monoclonal antibodies (ch14.18) is associated with significant pain requiring management with a high-dose opioid infusion. We present a case series of six children, for whom dexmedetomidine and hydromorphone infusions safely and effectively reduced the pain of ch14.18 therapy in the oncology ward setting."

      Read Full Article
    6. Agreement among measurements and estimations of glomerular filtration in children with cancer.

      "None of the three estimation formulae provided a reliable estimate of the index GFR. The mean difference was lowest between the revised Schwartz and the index GFR compared to the other two formulae and the index GFR. For the original Schwartz equation, age and prior receipt of chemotherapy were significant predictors of under- and overestimation. For the revised Schwartz equation, one age group (6-12 years) and a diagnosis of neuroblastoma actively receiving chemotherapy were positive risk factors for overestimation of the GFR."

      Read Full Article
    7. Exposure of neuroblastoma cell lines to imatinib results in the upregulation of the CDK inhibitor p27KIP1 as a consequence of c-Abl inhibition.

      "We provide evidence that in neuroblastoma cell lines a significant fraction of cellular c-Abl is phosphorylated on Tyr-245, consistent with an open and active conformation. Notably, exposure to imatinib did not affect Tyr-245 phosphorylation. Given the low affinity of active c-Abl for imatinib, these data provide a molecular explanation for the relatively high imatinib concentrations required to inhibit neuroblastoma cell proliferation."

      Read Full Article
    8. Silencing of CDC42 inhibits neuroblastoma cell proliferation and transformation.

      "Here, we found that increased expression of CDC42 correlated with undifferentiated neuroblastoma as compared to a more benign phenotype. CDC42 inhibition decreased cell growth and soft agar colony formation, and increased cell death in BE(2)-C and BE(2)-M17 cell lines, but not in SK-N-AS. In addition, silencing of CDC42 decreased expression of N-myc in BE(2)-C and BE(2)-M17 cells. Our findings suggest that CDC42 may play a role in the regulation of aggressive neuroblastoma behavior."

      Read Full Article
      Mentions: Surgery
    9. Proton radiotherapy for pediatric tumors: review of first clinical results.

      "Moreover, other possible applications are emerging, in particular for lymphoma and neuroblastoma. Although both photon and proton techniques allow similar target volume coverage, the main advantage of proton radiation therapy is to sparing of intermediate-to-low-dose to healthy tissues. This characteristic could translate into clinical reduction of side effects, including a lower risk for secondary cancers. The following review presents the state of the art of proton therapy in the treatment of pediatric malignancies."

      Read Full Article
      Mentions: Radiotherapy
    10. Pediatric Population Reference Value Distributions for Cancer Biomarkers and Covariate-Stratified Reference Intervals in the CALIPER Cohort.

      "This CALIPER study established a database of childhood reference intervals for 11 tumor biomarkers and revealed dramatic fluctuations in tumor marker concentrations between boys and girls and throughout childhood. In addition, important differences between the adult and pediatric population were observed, further highlighting the need for pediatric-specific reference intervals."

      Read Full Article
      Mentions: Diagnostics
    11. Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors.

      Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors.

      Cancer Chemother Pharmacol. 2014 Sep 26;

      Authors: Brennan RC, Furman W, Mao S, Wu J, Turner DC, Stewart CF, Santana V, McGregor LM

      Read Full Article
      Mentions: Refractory
    12. Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: A report from the children's oncology group phase I consortium.

      Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: A report from the children's oncology group phase I consortium.

      Pediatr Blood Cancer. 2014 Sep 24;

      Authors: Voss SD, Glade-Bender J, Spunt SL, DuBois SG, Widemann BC, Park JR, Leary SE, Nelson MD, Adamson PC, Blaney SM, Weigel B

      Read Full Article
      Mentions: COG
    13. Intracellular fragment of NLRR3 (NLRR3-ICD) stimulates ATRA-dependent neuroblastoma differentiation.

      Intracellular fragment of NLRR3 (NLRR3-ICD) stimulates ATRA-dependent neuroblastoma differentiation.

      Biochem Biophys Res Commun. 2014 Sep 22;

      Authors: Akter J, Takatori A, Islam S, Nakazawa A, Ozaki T, Nagase H, Nakagawara A

      Abstract We have previously idenitified neuronal leucine-rich repeat protein-3 (NLRR3) gene which was preferentially expressed in favorable human neuroblastomas as compared with unfavorable ones.

      Read Full Article
    14. Epidemiological and clinical characteristics of neuroblastoma in southern iran.

      Epidemiological and clinical characteristics of neuroblastoma in southern iran.

      Iran J Ped Hematol Oncol. 2014;4(3):89-96

      Authors: Bordbar M, Tasbihi M, Kamfiroozi R, Haghpanah S

      Abstract BACKGROUND: Neuroblastoma is the third most common malignancy in children with a very heterogeneous feature. In this study, the epidemiological and clinical characteristics of children with neuroblastoma treated in a referral oncology hospital in Shiraz, Southern Iran, were investigated.

      Read Full Article
      Mentions: Other Countries
    15. Second malignancies in patients with neuroblastoma: The effects of risk-based therapy.

      Second malignancies in patients with neuroblastoma: The effects of risk-based therapy.

      Abstract BACKGROUND: To investigate the incidence of second malignant neoplasms (SMN) for patients with neuroblastoma, we analyzed patients from the SEER database according to three treatment eras (Era 1: 1973-1989, Era 2: 1990-1996, and Era 3: 1997-2006) corresponding to the introduction of multi-agent chemotherapy, risk-based treatment, and stem cell transplant. PROCEDURES: The SEER database was mined for all patients with neuroblastoma or ganglioneuroblastoma.

      Pediatr Blood Cancer. 2014 Sep 23;

      Authors: Applebaum MA, Henderson TO, Lee SM, Pinto N, Volchenboum SL, Cohn SL

       

      Read Full Article
    16. Intragenic anaplastic lymphoma kinase (ALK) rearrangements: Translocations as a novel mechanism of ALK activation in neuroblastoma tumors.

      Intragenic anaplastic lymphoma kinase (ALK) rearrangements: Translocations as a novel mechanism of ALK activation in neuroblastoma tumors.

      Genes Chromosomes Cancer. 2014 Sep 23;

      Authors: Fransson S, Hansson M, Ruuth K, Djos A, Berbegall A, Javanmardi N, Abrahamsson J, Palmer RH, Noguera R, Hallberg B, Kogner P, Martinsson T

      Read Full Article
      Mentions: ALK
    17. The Discovery of I-BET726 (GSK1324726A), a Potent Tetrahydroquinoline ApoA1 Up-Regulator and Selective BET Bromodomain Inhibitor.

      The Discovery of I-BET726 (GSK1324726A), a Potent Tetrahydroquinoline ApoA1 Up-Regulator and Selective BET Bromodomain Inhibitor.

      J Med Chem. 2014 Sep 24;

      Authors: Gosmini R, Nguyen VL, Toum J, Simon C, Brusq JM, Krysa G, Mirguet O, Riou-Eymard AM, Boursier EV, Trottet L, Bamborough P, Clark H, Chung CW, Cutler L, Demont EH, Kaur R, Lewis AJ, Schilling MB, Soden PE, Taylor S, Walker AL, Walker MD, Prinjha RK, Nicodème E

      Read Full Article
    18. Combination of Single-Photon Emission Computed Tomography and Magnetic Resonance Imaging to Track 111In-Oxine-Labeled Human Mesenchymal Stem Cells in Neuroblastoma-Bearing Mice.

      Combination of Single-Photon Emission Computed Tomography and Magnetic Resonance Imaging to Track 111In-Oxine-Labeled Human Mesenchymal Stem Cells in Neuroblastoma-Bearing Mice.

      Mol Imaging. 2014 Sep 1;13(0):1-10

      Authors: Cussó L, Mirones I, Peña-Zalbidea S, García-Vázquez V, García-Castro J, Desco M

      Read Full Article
    19. Diastolic function in anthracycline-treated children.

      Diastolic function in anthracycline-treated children.

      Cardiol Young. 2014 Sep 23;:1-6

      Authors: Harahsheh A, Aggarwal S, Pettersen MD, L'Ecuyer T

      Abstract Background: Anthracyclines are effective medications for childhood cancer. Their limitation is the risk of cardiomyopathy. Although diastolic dysfunction has been described in patients who received anthracyclines, cardiac monitoring has focused on systolic function, which is abnormal in up to 41% of the patients.

      Read Full Article
    20. Efficacy and Safety of Dexmedetomidine Added to Caudal Bupivacaine in Pediatric Major Abdominal Cancer Surgery.

      Efficacy and Safety of Dexmedetomidine Added to Caudal Bupivacaine in Pediatric Major Abdominal Cancer Surgery.

      Pain Physician. 2014 Sep-Oct;17(5):393-400

      Authors: Fares KM, Othman AH, Alieldin NH

      Abstract BACKGROUND: Caudal analgesia has been prolonged by the addition of various adjuvants. Dexmedetomidine is a highly selective alpha-2 agonist with sedative and analgesic properties.

      Read Full Article
      Mentions: Surgery
    21. Radiation Therapy to the Primary and Postinduction Chemotherapy MIBG-Avid Sites in High-Risk Neuroblastoma.

      Radiation Therapy to the Primary and Postinduction Chemotherapy MIBG-Avid Sites in High-Risk Neuroblastoma.

      Int J Radiat Oncol Biol Phys. 2014 Sep 20;

      Authors: Mazloom A, Louis CU, Nuchtern J, Kim E, Russell H, Allen-Rhoades W, Krance R, Paulino AC

      Abstract PURPOSE: Although it is generally accepted that consolidation therapy for neuroblastoma includes irradiation of the primary site and any remaining metaiodobenzylguanidine (MIBG)-avid metastatic sites, limited information has been published regarding the efficacy of this approach. METHODS AND MATERIALS: Thirty patients with high-risk neuroblastoma were treated at 1 radiation therapy (RT) department after receiving 5 cycles of induction chemotherapy and ...

      Read Full Article
      Mentions: Radiotherapy
    22. Does Aggressive Surgical Resection Improve Survival in Advanced Stage 3 and 4 Neuroblastoma? A Systematic Review and Meta-analysis.

      Does Aggressive Surgical Resection Improve Survival in Advanced Stage 3 and 4 Neuroblastoma? A Systematic Review and Meta-analysis.

      Pediatr Hematol Oncol. 2014 Sep 23;

      Authors: Mullassery D, Farrelly P, Losty PD

      Abstract The role of surgery in the management of advanced staged neuroblastoma (NBL) is controversial. A systematic review and meta-analysis is reported to address robust evidence for curative "gross total tumor resection" (GTR) in Stage 3 and Stage 4 neuroblastoma.

      Read Full Article
      Mentions: Surgery
    1513-1536 of 1681 « 1 2 ... 61 62 63 64 65 66 67 ... 68 69 70 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video